Key result
Cardiovascular comorbidities increase mortality primarily in early-stage lung cancer, whereas their impact on prognosis is limited in advanced stages where tumor-related factors dominate.
Why the study?
Many factors contribute to mortality in lung cancer, including concomitant cardiovascular disease, but the prognostic impact of cardiovascular comorbidities and cardiotoxicity across different cancer stages warrants clarification.
Cardiovascular comorbidities significantly worsen the prognosis of lung cancer patients, emphasizing the importance of cardio-oncology evaluation to optimize both cardiac and oncological therapies.
Highlights need for early-stage cardio-oncology focus in lung cancer; leaves open optimal strategies for advanced disease.
Many factors contribute to mortality in lung cancer, including the presence of concomitant cardiovascular disease. In the treatment of early stage of lung cancer, the presence of comorbidities and occurence of cardiotoxicity may be prognostic. The effect of cardiotoxicity of radiotherapy and chemoradiotherapy on overall survival has been documented. Acute arterial and venous thromboembolic events seem to correlate with the degree of the histological malignancy, its clinical advancement, and even with optimal cardiac treatment, they may influence the survival time. In the case of high-grade and advanced lung cancer stage especially in an unresectable stadium, the prognosis depends primarily on the factors related to the histopathological and molecular diagnosis. Electrocardiographic and echocardiographic abnormalities may be prognostic factors, as they seem to correlate with the patient's performance status as well as tumor localization and size.
No takes yet. Share an insight, caveat, or question.
Mędrek et al. (2022) conducted a review in Lung cancer. Cardiovascular comorbidities vs. No cardiovascular comorbidities was evaluated on Prognosis and overall survival. Cardiovascular comorbidities increase mortality primarily in early-stage lung cancer, whereas their impact on prognosis is limited in advanced stages where tumor-related factors dominate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: